According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:
1. Amneal Pharmaceuticals (NASDAQ:AMRX)
The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: B.
Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 31, which is 6 points higher than the healthcare sector average of 25. It passed 10 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 27.74% over the past year, overperforming other healthcare stocks by 51 percentage points.
Amneal Pharmaceuticals has an average 1 year
price target of $13.50, an upside of 24.77% from Amneal Pharmaceuticals's current stock price of $10.82.
Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Ironwood Pharmaceuticals (NASDAQ:IRWD)
The Component Grade breakdown for Ironwood Pharmaceuticals (NASDAQ:IRWD) is: Value: A, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: B, and AI: A.
Ironwood Pharmaceuticals (NASDAQ:IRWD) has a Due Diligence Score of 3, which is -22 points lower than the healthcare sector average of 25. Although this number is below the industry average, our proven quant model rates IRWD as a "A".It passed 1 out of 33 due diligence checks and has weak fundamentals. Ironwood Pharmaceuticals has seen its stock lose -51.39% over the past year, underperforming other healthcare stocks by -28 percentage points.
3. Embecta (NASDAQ:EMBC)
Embecta (NASDAQ:EMBC) is the #3 top healthcare stock out of 1097 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: B.
Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 10 points higher than the healthcare sector average of 25. It passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -5.26% over the past year, overperforming other healthcare stocks by 18 percentage points.
Embecta has an average 1 year
price target of $18.50, an upside of 38.68% from Embecta's current stock price of $13.34.
Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.